JSR Life Sciences Launches 'Similis Bio' to Help Partners Accelerate Biosimilar Development
10.5.2022 15:00:00 EEST | Business Wire | Press release
JSR Life Sciences, LLC (JSR) today announced the launch of a new business division, Similis Bio (Similis), which will operate a partnering program designed to help biopharmaceutical companies improve the efficiency and cost of biosimilar development. Similis will rely on core expertise in developing and manufacturing biologics to mitigate the challenges inherent in biosimilar drug development.
Similis provides biosimilar drug developers with solutions designed to accelerate development timelines and lower costs. By offering complete analytical and process development packages, Similis supplies companies with data to determine an appropriate biosimilar target, accelerate early program development, and reduce analytical costs. Data packages include reference product data, analytical procedures, process expertise, and CMC templates from a centralized model designed to give partners access to higher quality biosimilar packages at a lower cost than other development models.
Additionally, Similis will establish co-development agreements with partner companies to start the development of multiple biosimilar programs in parallel, giving partners an exclusive right, but not an obligation, to purchase multiple programs. JSR designed this collaboration model to reduce the risk from program cancellations and extend market analysis timelines.
“This model will enable changes in strategy far beyond traditional drug development approaches by centralizing reference product data and expertise under one roof,” said JSR Life Sciences’ Chief Technology Officer Jean-Pierre Wery. “Similis brings the broad expertise of JSR Life Sciences companies together to jump-start the development of promising biosimilars. By improving timelines and development costs for drug makers, more biosimilars can be brought to market faster. Ultimately, that means more choice and lower costs for patients.”
Biosimilars—the generic form of FDA-approved biologics—are derived from living organisms, making them inherently complex. Unlike small-molecule generic drugs, biosimilars cannot fully replicate their brand-name counterparts, so an array of analytical data must be collected to ensure they sufficiently reflect biosimilarity to the FDA-approved reference products to which they are being compared. This process requires costly and significant investment in expertise, state-of-the-art technology, and extensive data gathering, including rigorous clinical trials to ensure a biosimilar's safety and efficacy. JSR launched Similis Bio to mitigate these barriers to market entry and promote more productive development programs.
For more information about Similis Bio visit: JSRLifeSciences.com/similis.
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005401/en/
Contact information
Missy Bindseil
JSR Life Sciences Company Inquiries
Director, Marketing & Communications
mbindseil@jsr-nahq.com
Mike Beyer
JSR Life Sciences Media Inquiries
Sam Brown Inc.
mikebeyer@sambrown.com
+1 312-961-2502
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Enhances Support for AI Workloads at Massive Scale23.6.2026 17:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced the release of StorageGRID 12.1, designed to help customers scale AI and other modern workloads with a federated global namespace. The new capabilities improve how data is accessed, processed, and managed across distributed environments to support AI data pipelines, data lakes, and modern object-based applications. Organizations are contending with rapid growth in unstructured data to serve AI workloads while also managing that data across increasingly distributed hybrid environments. In its Object Storage Solutions Landscape, Q1 2026 report, Forrester notes that the rise of generative AI has pushed object storage further into an AI‑optimized data platform beyond its historical uses supporting enterprise data strategies with scalable, durable storage for unstructured data, media, and backups. The updates to NetApp StorageGRID enable organizations to leverage their object data for these emerging uses wi
Otonal Launches Localization Service to Adapt English Podcasts and Audio Ads for the Japanese Market23.6.2026 17:00:00 EEST | Press release
Otonal Inc., a Tokyo-based digital audio advertising and podcast technology company, has officially launched a specialized audio localization service designed to help global brands and media companies adapt their English-language podcasts and audio advertisements for the Japanese market. Audio Ad Localization https://otonal.co.jp/en/audioad-localization/ Podcast Localization https://otonal.co.jp/en/podcast-localization/ While many translation vendors focus on text-based, one-size-fits-all translation, Otonal’s service addresses the distinct challenges of audio-first localization. The service goes beyond standard translation by rebuilding scripts for spoken Japanese, ensuring precise 15- and 30-second ad timings, adapting the content to local cultural context, and casting native Japanese voice talent suited to the content and delivery environment to maintain brand authority and tone. Japan ranks among the world's leading economies and is one of Asia’s largest advertising markets, making
GigaDevice and Qt Group Announce Global Partnership to Advance the Embedded GUI Ecosystem23.6.2026 17:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially entered a strategic partnership with Qt Group, a global leader in software design, development, and quality assurance solutions. Leveraging the GD32H7 high-performance MCU series, the two companies will collaborate to optimize and enhance embedded GUI solutions, enabling developers to create more intuitive, visually rich, and responsive user experiences. This collaboration further expands GigaDevice’s ecosystem strategy in advanced human-machine interface (HMI) and establishes a solid foundation for future innovation across smart industry solutions, energy storage systems, smart home devices, and consumer electronics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623351273/en/ GigaDevice and Qt Group Announce Global Partnership to Advance the Embedded GUI Ecosystem As IoT,
Andersen Global Adds Andersen in Indonesia23.6.2026 16:30:00 EEST | Press release
Andersen Global strengthens its footprint in Southeast Asia as VDB Loi in Indonesia rebrands to Andersen in Indonesia, becoming the newest member firm to join the organization. Andersen in Indonesia provides tax and legal advisory services to multinational companies and foreign investors operating in the Indonesian market. The firm combines decades of market experience with a practical approach focused on delivering clear, tailored guidance across complex regulatory and cross-border matters. “Adopting the Andersen brand reflects our commitment to providing clients with high-quality, practical tax and legal advice supported by broader international collaboration,” said Tommy Hendharto Oetomo, managing partner of Andersen in Indonesia. “Clients operating in Indonesia require increasingly coordinated cross-border support. Becoming a member firm strengthens our ability to deliver that service with consistency and clarity.” “Indonesia remains an important market for organizations investing
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 16:30:00 EEST | Press release
Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Research and Development and Chief Medical Officer, Healthcare business of Merck. “By leveraging Saturnus' expertise and cutting-edge approach, we can build upon our armed antibodies capabilities and explore novel directions to rapidly bring new, targeted treatments to patients.” “The launch of Saturnus through a foundati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom